Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Follow-Up Studies
Humans
Killer Cells, Lymphokine-Activated
/ transplantation
Lymphoma, Follicular
/ pathology
Maintenance Chemotherapy
Male
Middle Aged
Prednisone
/ administration & dosage
Prospective Studies
Rituximab
/ administration & dosage
Vincristine
/ administration & dosage
antibody-dependent cellular cytotoxicity
follicular lymphoma
lymphokine-activated killer cells
maintenance treatment
rituximab
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
07
10
2019
accepted:
16
12
2019
pubmed:
5
3
2020
medline:
26
1
2021
entrez:
5
3
2020
Statut:
ppublish
Résumé
Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after this treatment. We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy. This open, prospective, phase II, single-arm study assessed safety and efficacy of ex vivo expanded LAK cells in 20 FL-remission patients following rituximab maintenance. Mononuclear cells were obtained in odd rituximab cycles and stimulated with interleukin 2 (IL-2) for 8 weeks, after which >5 × 10
Substances chimiques
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1064-1073Subventions
Organisme : Ministerio de Sanidad, Política Social e Igualdad of the Spanish Government
ID : TRA-112
Pays : International
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Cancer Therapy Evaluation ProgramCommon Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. (2006). [cited 2003 Mar 31] Available from: http://ctep.cancer.gov
Berdeja, J.G., Hess, A., Lucas, D.M., O’Donnell, P., Ambinder, R.F., Diehl, L.F., Carter-Brookins, D., Newton, S. & Flinn, I.W. (2007) Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clinical Cancer Research, 13, 2392-2399.
Bollard, C.M. & Barrett, A.J. (2014) Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology ASH Education Program, 2014, 565-569.
Casulo, C., Byrtek, M., Dawson, K.L., Zhou, X., Farber, C.M., Flowers, C.R., Hainsworth, J.D., Maurer, M.J., Cerhan, J.R., Link, B.K., Zelenetz, A.D. & Friedberg, J.W. (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. Journal of Clinical Oncology, 33, 2516-2522.
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V.; International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
Fayers, P.M., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D. & Bottomley, A. (2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn.European Organisation for Research and Treatment of Cancer, Brussels.
Gao, X., Mi, Y., Guo, N., Xu, H., Xu, L., Gou, X. & Jin, W. (2017) Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Frontiers in Immunology, 8, 774.
García-Muñoz, R., López-Díaz-de-Cerio, A., Feliu, J., Panizo, A., Giraldo, P., Rodríguez-Calvillo, M., Grande, C., Pena, E., Olave, M., Panizo, C. & Inogés, S. (2016) Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. Immunology Research, 64, 548-557.
Gascoyne, R.D., Nadel, B., Pasqualucci, L., Fitzgibbon, J., Payton, J.E., Melnick, A., Weigert, O., Tarte, K., Gribben, J.G., Friedberg, J.W., Seymour, J.F., Cavalli, F. & Zucca, E. (2017) Follicular lymphoma: state-of-the-art ICML workshop in Lugano 2015. Hematological Oncology, 35, 397-407.
Huet, S., Sujobert, P. & Salles, G. (2018) From genetics to the clinic: a translational perspective on follicular lymphoma. Nature Reviews Cancer, 18, 224-239.
Kahl, B.S. & Yang, D.T. (2016) Follicular lymphoma: evolving therapeutic strategies. Blood, 127, 2055-2063.
Kannan, G.S., Aquino-Lopez, A. & Lee, D.A. (2017) Natural killer cells in malignant hematology: a primer for the non-immunologist. Blood Reviews, 31, 1-10.
Ma, B. & Ujjani, C. (2017) The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer Management and Research, 9, 103-113.
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J.F., Townsend, W., Trněný, M., Wenger, M., Fingerle-Rowson, G., Rufibach, K., Moore, T., Herold, M. & Hiddemann, W. (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. The New England Journal of Medicine, 377, 1331-1344.
Okroj, M., Österborg, A. & Blom, A.M. (2013) Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treatment Reviews, 39, 632-639.
Pittari, G., Filippini, P., Gentilcore, G., Grivel, J.C. & Rutella, S. (2015) Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Frontiers in Immunology, 6, 230.
Rosalia, R.A., Arenas-Ramirez, N., Bouchaud, G., Raeber, M.E. & Boyman, O. (2014) Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Current Opinions in Chemical Biology, 23, 39-46.
Salles, G., Seymour, J.F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Fermé, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. The Lancet, 377, 42-51.
Salles, G.A., Seymour, J.F., Feugier, P., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Bouabdallah, R., Catalano, J., Pauline, B., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., Gomes da Silva, M., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Coiffier, B. & Tilly, H. (2013) Updated 6 Year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood, 122, 509.
Schultz, K.R., Klarnet, J.P., Peace, D.J., Cheever, M.A., Badger, C.C., Bernstein, I.D. & Greenberg, P.D. (1990) Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Research, 50, 5421-5425.
Shafer, D., Smith, M.R., Borghaei, H., Millenson, M.M., Li, T., Litwin, S., Anad, R. & Al-Saleem, T. (2013) Low NK cell counts in peripheral are associated with inferior overall survival in patients with follicular lymphoma. Leukemia Research, 37, 1213-1215.
Vidal, L., Gafter-Gvili, A., Salles, G., Dreyling, M.H., Ghielmini, M., Hsu Schmitz, S.F., Pettengell, R., Witzens-Harig, M. & Shpilberg, O. (2011) Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. Journal of the National Cancer Institute, 103, 1799-1806.